Publication | Closed Access

Cardioprotection by Recombinant Human Erythropoietin Following Acute Experimental Myocardial Infarction: Dose Response and Therapeutic Window

ThrombosisHeart FailureCardiovascular DiseaseAtherosclerosisPharmacologyDose ResponseRecombinant Human ErythropoietinPharmacotherapyAcute Myocardial InfarctionCardiovascular ToxicityMedicineCardiologyTherapeutic WindowMyocardial Infarction